Comparing two eye injections for diabetic macular edema
Treatments studied
Part of Eyes & vision clinical trials.
This trial compares two standard anti-VEGF injections (aflibercept and bevacizumab) for people with diabetic macular edema who have not recently had this treatment. The goal is to see which drug works better over three monthly doses to improve vision and reduce retinal swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes (not type 1)
- You are not using insulin to manage your diabetes
- You have diabetic macular edema (swelling in the center of the retina) that affects your vision
- You have not had an anti-VEGF injection in the eye in the last 3 months
- You have not had certain eye surgeries or laser treatments in the past 3 months, and no major surgery in the past year
- You do not have uncontrolled high blood pressure, bleeding problems, or a history of blood clots
- You are not pregnant or nursing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This trial tests if combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than aflibercept alone for people with diabetic macular edema caused by inflammation. It aims to find the best first treatment for improving vision and reducing swelling.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
Hear when a new Diabetic Maculopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.